Actively Recruiting
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Led by Bindu R Potugari · Updated on 2026-04-23
35
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
Sponsors
B
Bindu R Potugari
Lead Sponsor
G
Gilead Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination. The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors. Participants in the trial will: * receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient. * CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks. * provide tissue (optional) and blood for additional testing (learn about the cancer).
CONDITIONS
Official Title
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to give informed consent for the trial
- Male or female aged 18 years or older
- Histologically or cytologically confirmed small cell lung cancer with extensive stage or locally advanced disease not suitable for curative radiation
- Received at least four cycles of platinum plus etoposide chemotherapy and 2-3 cycles of atezolizumab or durvalumab immunotherapy
- No disease progression on restaging CT after 4-6 cycles of chemotherapy and immunotherapy
- ECOG performance status of 0 to 2
- No active uncontrolled HIV, hepatitis B, or hepatitis C infections (well-controlled infections on treatment allowed)
- Stable and asymptomatic brain metastases allowed
- Adequate bone marrow, kidney, and liver function
You will not qualify if you...
- Significant kidney failure requiring dialysis or severe liver disease
- Presence of leptomeningeal disease
- Recent heart failure or acute coronary disease within 3 months
- Unable to receive or discontinued immunotherapy with chemotherapy due to immune-related side effects
- Active chronic inflammatory bowel disease or recent gastrointestinal perforation within 6 months
- Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or other immunotherapy agents targeting T-cell receptors within 12 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henry Ford Cancer- Detroit
Detroit, Michigan, United States, 48202
Actively Recruiting
Research Team
B
Bindu Potugari, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here